Han Kun Law Offices

License-in/out transactions have become a key strategic approach for innovative drug and medical device (including medical aesthetics) companies to expedite the research and development of the products and expand market presence. According to statistics, the total deal value of business development (BD) transactions in life sciences sector in China has reached a historic high of over 60 billion US Dollars in 2024. The proportion of license-out transactions continues to rise[2], highlighting the strong momentum of China's biopharmaceutical industry in its global expansion...

Following the economic and financial crisis in 2007, in view of the significant weakness in the resiliency of banks and other market participants to financial and economic shocks, in particular from over-the-counter (OTC) derivatives transactions, the Group of Twenty (G20) agreed on the necessity of improved transparency in the OTC derivatives markets and further regulation of OTC derivatives, and initiated a reform programme in 2009 to reduce the systemic risk from OTC derivatives which comprise of the following four elements: All standardised OTC derivatives should be traded on exchanges or electronic platforms, where appropriate...

On March 14, 2025, the winners of the Chambers Greater China Region (PRC Firms) Awards 2025 were announced during a ceremony held in Shanghai.  Han Kun won one of the most prestigious awards, "China (PRC Firms) Corporate & Finance Law Firm of the Year".  This is the second consecutive year Han Kun has been honored since winning the award in 2024.  Han Kun lawyers Mr. Kelvin Gao, Mr. Vincent Song, and Mr. Micheal He attended the ceremony on behalf of Han Kun to receive the honor...

Recently, the Shanghai International Arbitration Center (SHIAC) made a ruling on a new drug development license-in transaction dispute with significant industry benchmark value. Han Kun Law Offices successfully represented the licensee in defending against the licensor's request for contract termination, preserving our client's commercial interests.  The case involves the understanding and application of typical terms and legal issues in license-in/license-out transactions within the biopharmaceutical industry...